Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Iā¦ (NCT05908825) | Clinical Trial Compass
CompletedNot Applicable
Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults
United States34 participantsStarted 2023-06-22
Plain-language summary
This is a split-face, double-blind, placebo-controlled study assessing the use of a novel exfoliative serum with a chemical peel to improve photodamage in healthy female subjects between the ages of 30 and 65 years, inclusive, with Fitzpatrick skin types I-VI.
Who can participate
Age range30 Years ā 65 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Healthy female subjects aged between 30 and 65 years, inclusive
ā. Fitzpatrick skin type I-VI
ā. All skin types, including sensitive skin
ā. Mild to moderate severity (score of 3 to 6; modified Griffiths scale) of the following attributes on the global face:
ā. Smoothness, tactile and visual
ā. Dark spot intensity
ā. Hyperpigmentation
ā. Clarity
Exclusion criteria
ā. Subjects that are being treated for cancer or have a history of facial skin cancer on the test areas
ā. Subjects with sunburn, moderate to pronounced suntan, pronounced asymmetric skin aging, tattoos, scars or other disfiguration, dilated vessels or other conditions on the test area that might influence the test results
ā. Subjects currently taking certain medications which in the opinion of the Investigators may interfere with the study. This includes but not limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids \[steroid nose drops, inhalers and/or eye drops are permitted\]), and immunosuppressive drugs
ā. Subjects with self-reported, uncontrolled systemic disease which, in the opinion of the Investigator, may hinder either the subject's ability to perform all responsibilities of the trial or the Investigator's ability to perform assessments
ā. Women known to be pregnant, nursing or planning to become pregnant
ā. Subjects participating in other facial clinical studies
ā. Subjects who have routinely used an alpha-hydroxy-acid (AHA) or a beta-hydroxy-acid (BHA) containing product within two weeks or Retin-A, Retin-A Micro, Renova, Differin, Avita, Tazorac, or Soriatane within 8 weeks of the study start or have taken Isotretinoin within one year of the study start. Subjects who have used Retinol in the last 4 weeks
ā. Subjects with current flaring moderate to severe inflammatory acne